Amgen (HAM:AMG) Accumulated other comprehensive income (loss) : €-175 Mil (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Amgen Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Amgen's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €-175 Mil.

Amgen's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2023 (€-118 Mil) to Dec. 2023 (€-265 Mil) but then increased from Dec. 2023 (€-265 Mil) to Mar. 2024 (€-175 Mil).

Amgen's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 (€-704 Mil) to Dec. 2022 (€-218 Mil) but then declined from Dec. 2022 (€-218 Mil) to Dec. 2023 (€-265 Mil).

Amgen Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Amgen's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Accumulated other comprehensive income (loss) Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-475.20

-809.67

-704.46

-218.06

-265.01

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-250.31	-258.44	-118.06	-265.01	-174.80

Amgen Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Amgen Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Amgen's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (HAM:AMG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HAM:AMG) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.